Cancer Vaccines Set to Make Major Impact on Cancer Market
The value of the market for cancer vaccines has the potential to reach $6 billion by 2010, according to Arrowhead Publishers, who have just released their new report Cancer Vaccines: Measuring Market Potential. (http://www.arrowheadpublishers.com/CancerVaccines.html)
(PRWEB) January 5, 2005 -- Vaccines represent fresh new treatment options for
patients diagnosed with melanoma, prostate cancer, colorectal cancer, breast
cancer, lung cancer, pancreatic cancer, and other life-threatening cancers.
There are currently over twenty Phase III trials ongoing for various indications
and new approvals may come as early as 2005.
This report includes the
latest clinical data and analysis concerning the leading vaccines and the
companies making them, allowing the reader to benchmark the competition and
determine need in this growing field.
In addition, financial forecasts
are provided for vaccines set to make an impact on distinct cancer markets.
Moreover, their upcoming market entrance is discussed within the context of
current and future biologic and small-molecule competition.
Therapeutic
cancer vaccines have the potential to strengthen the body's natural defenses
against cancers that have already developed. These vaccines may thus, prevent
the further growth of existing cancers, prevent recurrence of treated cancers,
or kill cancer cells not killed by other treatments.
This new 232-page
report provides an overview of the emerging market for cancer vaccines and
measures their potential impact on a wide range of cancer markets. It is
designed to provide the information, insight, and analysis necessary to an
understanding of how cancer vaccines will impact the biotech and pharmaceutical
marketplace. Those in the field of cancer therapy will want to read this report
in order to better understand where and how vaccines will make a difference in
future cancer therapy.
Cancer Vaccines: Measuring Market Potential
•
Gauges the potential of key vaccine products nearing commercialization.
•
Analyzes the results of key clinical trials as a means of determining future
success in the market.
• Forecasts financial growth of the cancer vaccine
market through 2010.
• Assesses the competition from cytotoxics and other
biologics in six key cancer markets.
• Provides valuable data concerning
patient populations, survival rates, and global epidemiology
• Identifies and
discusses trends and issues that will have a significant impact on the cancer
vaccine market.
• Profiles the leading companies in the field and provides
valuable information and analysis concerning their lead vaccine
candidates.
Contact:
Sales Department
952-474-5203
www.arrowheadpublishers.com
# # #
Source : http://www.prweb.com/releases/2005/1/prweb193798.htm